
Questions to ask your doctor about comprehensive biomarker testing for lung cancer



Comprehensive biomarker testing can help your healthcare team identify your appropriate treatment options.

Knowing your non-small cell lung cancer's biomarkers can help you and your doctor make fully informed decisions about how your cancer will be treated. Ask your healthcare team to perform comprehensive biomarker testing at any decision point before new treatment, including upon diagnosis, recurrence, or progression.



			rehensive biomarker testi	ing?"
<u>(×)</u> If no, o	ask "When	will my tumor be	tested?"	
<u>_\</u> If yes, (ask "What c	do my results mea	n for my individualized tree	atment
lf yes, skip :	section 2 an	d move to section	3.	
			a 3. arker testing, ask these	questi
Before yo	u get comp		arker testing, ask these	questi
Before yo	u get comp	orehensive biom	arker testing, ask these	quest

	"How are the tests performed?" "How long will it take to get the test results?"									
	"Are there any limitations of comprehensive biomarker testing?"									
	 "Will insurance pay for these tests?" 3 After testing, ask these questions: "Did you test me for these biomarkers?" 									
3										
	EGFR		ROSI BRAF V600E	 NTRK MET exon 14 skipping 	RET PD-L1					
	"What are the results of these tests?"									
	"Can I get a copy of my test results?"									
	[F]_ If the test results are negative, ask "Should I be retested?"									
	If the test results are not clear, ask "Should I be retested? If yes, why and when?"									

"If I've tested positive for any biomarkers, are there any FDA-approved medicines that target my specific type of non-small cell lung cancer?"

"Are there any clinical trials open to me based on these results?"

Additional notes

Know your biomarkers. Know your options.

To learn more about biomarkers and to read stories by lung cancer patients and survivors who have experienced comprehensive biomarker testing, visit LUNGevity.org/NoOneMissed

No One Missed is brought to you by the LUNGevity Foundation and made possible with the support of AstraZeneca, Amgen, and Genentech, a member of the Roche Group.



Genentech

AMGEN

